Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia

Neurology
C P Watson, N Babul

Abstract

Although opioid analgesics are used in the management of neuropathic pain syndromes, evidence of their efficacy remains to be established. We evaluated the clinical efficacy and safety of oxycodone in neuropathic pain using postherpetic neuralgia as a model. Patients with postherpetic neuralgia of at least moderate intensity were randomized to controlled-release oxycodone 10 mg or placebo every 12 hours, each for 4 weeks, using a double-blind, crossover design. The dose was increased weekly up to a possible maximum of 30 mg every 12 hours. Pain intensity and pain relief were assessed daily, and steady (ongoing) pain, brief (paroxysmal) pain, skin pain (allodynia), and pain relief were recorded at weekly visits. Clinical effectiveness, disability, and treatment preference were also assessed. Fifty patients were enrolled and 38 completed the study (16 men, 22 women, age 70+/-11 years, onset of postherpetic neuralgia 31+/-29 months, duration of pain 18+/-5 hours per day). The oxycodone dose during the final week was 45+/-17 mg per day. Compared with placebo, oxycodone resulted in pain relief (2.9+/-1.2 versus 1.8+/-1.1, p=0.0001) and reductions in steady pain (34+/-26 versus 55+/-27 mm, p=0.0001), allodynia (32+/-26 versus 50+/-30...Continue Reading

Citations

Jan 11, 2005·Arthritis and Rheumatism·Maren L MahowaldPeter Majeski
Feb 11, 2003·Diabetes/metabolism Research and Reviews·Andrew J M Boulton
Sep 5, 2002·Muscle & Nerve·David Lacomis
Jan 7, 2003·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Ian Gilron, Joan M Bailey
Feb 3, 2005·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Douglas Hardy
Aug 9, 2005·Der Internist·D Rothstein, M Zenz
Jul 16, 2008·Der Nervenarzt·S SternbergA May
Jun 28, 2006·European Journal of Clinical Pharmacology·Ariel BergerGerry Oster
Jun 16, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Claudio CartoniMaria Teresa Petrucci
Jan 16, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Ariel BergerGerry Oster
Sep 20, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·W GreinerR Sabatowski
Aug 30, 2008·HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery·Joseph H FeinbergAlita Gonsalves
Sep 3, 2011·HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery·Joseph H Feinberg, Jeffrey Radecki
Jun 19, 2013·Current Diabetes Reports·Roy Freeman
Mar 20, 2002·Current Neurology and Neuroscience Reports·A Carver, K Foley
Mar 17, 2001·Current Pain and Headache Reports·M S Wallace
Nov 5, 2002·Current Pain and Headache Reports·David A O'Gorman, Srinivasa N Raja
May 2, 2003·Current Pain and Headache Reports·Richard BarbanoRobert H Dworkin
May 2, 2003·Current Pain and Headache Reports·E Daniela Hord, Anne Louise Oaklander
May 24, 2005·Current Pain and Headache Reports·Nathaniel Katz, Christine Benoit
Sep 10, 2008·Current Pain and Headache Reports·Douglas A DobeckiMark S Wallace
Jan 12, 2007·Current Pain and Headache Reports·Sean Mackey, Steven Feinberg
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Patrick Henson, Stephen Bruehl
Aug 7, 2001·Current Treatment Options in Neurology·Larry E. Davis, Molly K. King
Nov 11, 2010·Current Treatment Options in Neurology·Srinivasan SanjayRaghavan Lavanya
Oct 1, 2003·Current Treatment Options in Neurology·Ok Yung Chung, Stephen P. Bruehl
May 26, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A Ordóñez GallegoE Espinosa Arranz
Mar 5, 2013·American Journal of Clinical Dermatology·Emily Yiping GanHong Liang Tey
Nov 28, 2012·Clinical Drug Investigation·Phaedra JohnsonMichael Sweeney
Oct 31, 2003·Journal of Pain and Symptom Management·Roger ChouMark Helfand
May 24, 2005·Journal of Pain and Symptom Management·Eija Kalso
Oct 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ada DelaneySusan M Fleetwood-Walker
Jun 1, 2002·Obstetrics and Gynecology·Anne Louise Oaklander, Julia G Rissmiller
Apr 6, 2004·The Orthopedic Clinics of North America·David J GormanAshish D Diwan
May 21, 1999·Lancet·R H Dworkin
Dec 12, 2003·Clinical Therapeutics·Brett R Stacey, Robert L Glanzman
Mar 15, 2003·Clinical Therapeutics·Miroslav Backonja, Robert L Glanzman
Jan 11, 2001·Pharmacology & Therapeutics·R D MacPherson
Aug 26, 2003·Advanced Drug Delivery Reviews·David Borsook
Feb 21, 2002·Neurologic Clinics·A C Carver, K M Foley
Oct 31, 2001·Acta Anaesthesiologica Scandinavica·H Breivik
Aug 26, 2006·Nature Clinical Practice. Neurology·Nanna B Finnerup, Troels S Jensen
Jun 28, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Minoru NaritaTsutomu Suzuki
Nov 30, 2006·Pain Practice : the Official Journal of World Institute of Pain·M Pappagallo, A D Rosenberg
Dec 13, 2006·Pain Practice : the Official Journal of World Institute of Pain·C Peter N Watson, Anne Louise Oaklander
Sep 18, 2001·European Journal of Pain : EJP·P L Dellemijn
Jan 19, 2002·European Journal of Pain : EJP·R D Helme

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.